Currently set to Index
Currently set to Follow
search
ask age2b
CART 0

Randomized Controlled Trial: Partial Hydrolyzation of Casein Protein in Milk Decreases Gastrointestinal Symptoms in Subjects with Functional Gastrointestinal Disorders

By AGE2B team
June 23, 2021
0
0

Main idea: The results suggest that the partial hydrolyzation of milk proteins (mainly casein) reduces subjective symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism remains to be resolved.

Abstract

Unspecified gastrointestinal symptoms associated with milk consumption are common. In addition to lactose also other components of milk may be involved. The current research studied whether the partial hydrolyzation of milk proteins would affect gastrointestinal symptoms in subjects with functional gastrointestinal disorders. In a randomized, placebo-controlled crossover intervention, subjects (n = 41) were given ordinary or hydrolyzed high-protein, lactose-free milkshakes (500 mL, 50 g protein) to be consumed daily for ten days. After a washout period of ten days, the other product was consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was completed at the beginning of the study and at the end of both study periods. Blood and urine samples were analyzed for markers of inflammation, intestinal permeability, and immune activation. Both the IBS-SSS score and total symptom were significantly reduced when participants consumed the hydrolyzed product. Less bloating was reported during both study periods when compared with the baseline (p < 0.01 for both groups). Flatulence (p = 0.01) and heartburn (p = 0.03) decreased when consuming the hydrolyzed product but not when drinking the control product. No significant differences in the levels of inflammatory markers (tumor necrosis factor-alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid-binding protein 2, FABP2), or immune activation (1-methylhistamine) were detected between the treatment periods.

Source MDPI

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.